ADMA Biologics (ADMA) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ADMA Hot Sheet
Join SI Premium – FREE
ADMA Biologics (NASDAQ: ADMA) reported Q2 EPS of ($0.03), in-line with the analyst estimate of ($0.03). Revenue for the quarter came in at $60.13 million versus the consensus estimate of $55.5 million.
For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
- Stifel Positive on Rapport Therapeutics (RAPP): 'remains on track to share longer-term safety data from the ph2a in 4Q26'
- Grainger (GWW) Tops Q3 EPS by 87c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
